Last reviewed · How we verify
Photodyn (Hematoporphyrin)
Photodyn (generic name: Hematoporphyrin) is a hematoporphyrin Small molecule drug developed by Hepatopancreatobiliary Surgery Institute of Gansu Province. It is currently in Phase 1 development for Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia, High Grade Dysplasia associated with Barrett's Esophagus, Malignant tumor of esophagus. Also known as: ERCP stents.
Photodyn works by being activated by light, which then kills cancer cells through a process called photodynamic therapy.
Photodyn (Hematoporphyrin) is a small molecule drug in the hematoporphyrin class, originally developed by the Hepatopancreatobiliary Surgery Institute of Gansu Province and currently owned by the same institution. It is used to treat various cancers, including non-small cell lung cancer, esophageal cancer, and high-grade dysplasia associated with Barrett's esophagus. Photodyn works by being activated by light, which then kills cancer cells. The commercial status of Photodyn is unclear, but it is approved for use in certain indications. Key safety considerations include the potential for skin and eye irritation.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hematoporphyrin |
|---|---|
| Also known as | ERCP stents |
| Sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province |
| Drug class | hematoporphyrin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Imagine your body's cells are like houses, and cancer cells are like houses on fire. Photodyn is like a special kind of paint that, when exposed to light, makes the cancer cells burn up and die. This process is called photodynamic therapy and it's a way to target and kill cancer cells without harming healthy cells.
Approved indications
- Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
- High Grade Dysplasia associated with Barrett's Esophagus
- Malignant tumor of esophagus
- Non-small cell lung cancer
Common side effects
Key clinical trials
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (PHASE1)
- Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (PHASE1)
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (PHASE2)
- Sonodynamic-Chemoradiotherapy Integration in Glioblastoma (PHASE2)
- Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis (PHASE2)
- Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (PHASE1,PHASE2)
- Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (PHASE1)
- Photodynamic Therapy for Cholangiocarcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Photodyn CI brief — competitive landscape report
- Photodyn updates RSS · CI watch RSS
- Hepatopancreatobiliary Surgery Institute of Gansu Province portfolio CI
Frequently asked questions about Photodyn
What is Photodyn?
How does Photodyn work?
What is Photodyn used for?
Who makes Photodyn?
What is the generic name of Photodyn?
Is Photodyn also known as anything else?
What drug class is Photodyn in?
What development phase is Photodyn in?
Related
- Drug class: All hematoporphyrin drugs
- Manufacturer: Hepatopancreatobiliary Surgery Institute of Gansu Province — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
- Indication: Drugs for High Grade Dysplasia associated with Barrett's Esophagus
- Indication: Drugs for Malignant tumor of esophagus
- Also known as: ERCP stents
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing